Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013 by The Associated Press

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the U.S. to getting a long series of uncomfortable shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction.

Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

Explore further: 'Apple allergy': Symptoms could be significantly reduced with apple-allergen treatment

shares

Related Stories

'Apple allergy': Symptoms could be significantly reduced with apple-allergen treatment

October 19, 2012
The food allergy associated with birch pollen is a condition commonly found alongside an allergy to birch pollen. Sufferers are plagued by swelling and reddening or itching in the mouth and throat area, for example when they ...

Life saving treatment for fire ant allergy under used

March 4, 2013
Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma ...

The year 2040: Double the pollen, double the allergy suffering?

November 9, 2012
With this year's unseasonably warm temperatures and extended seasons, many have coined 2012 as being the worst for allergies. But if you thought your symptoms were worse than ever, just wait until the year 2040.

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.